SCHEMBL1695389

SCHEMBL1695389

CCN(CC)CCCCN(C)c1ccnc2ccc(OC)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.47
ADRA1D P25100 2/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
KIT P10721 1/20 0.47
LMNA P02545 4/20 0.43
USP2 O75604 4/20 0.43
TP53 P04637 3/20 0.43
CYP3A4 P08684 3/20 0.43
CASP1 P29466 3/20 0.43
CASP7 P55210 3/20 0.43
HBB P68871 3/20 0.43
HSD17B10 Q99714 3/20 0.43
CYP1A2 P05177 3/20 0.43
APP P05067 2/20 0.43
CYP2D6 P10635 2/20 0.43
TSHR P16473 2/20 0.43
BRCA1 P38398 2/20 0.43
HIF1A Q16665 2/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1695271 0.79 HRH3 (0.60) SLC6A2HRH3
SCHEMBL21321494 0.77 LMNA (0.55) HTR1AADRA1DADRA1AADRA1BLMNA
SCHEMBL1695428 0.76 APP (0.64) HTR1AADRA1DADRA1AADRA1BLMNA
SCHEMBL1695452 0.75 CHRM2 (0.43) HTR1AADRA1DLMNAHSD17B10APP
SCHEMBL3454269 0.75 CHRM2 (0.43) ADRA1DKITLMNAHSD17B10APP
SCHEMBL3454549 0.75 KCNH2 (0.60) HTR1AADRA1DLMNACYP3A4HSD17B10
SCHEMBL1695377 0.72 HRH3 (0.54) ADRA1DLMNACHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL29641695 0.71 HTR1A (0.65) HTR1AADRA1DADRA1AADRA1BKIT
SCHEMBL13740603 0.71 USP2 (0.62) HTR1AADRA1DLMNAUSP2TP53
SCHEMBL1695430 0.70 MTNR1A (0.44) HTR1AADRA1DADRA1AADRA1BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023043953-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2023-03-23 WO disclosed
EP-4126066-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY Avidity Biosciences, Inc. (US) 2023-02-08 EP disclosed
EP-4121063-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY Avidity Biosciences, Inc. (US) 2023-01-25 EP disclosed
EP-3898693-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF Avidity Biosciences, Inc. (US) 2021-10-27 EP disclosed
WO-2021195469-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2021-09-30 WO disclosed
WO-2021188390-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2021-09-23 WO disclosed
EP-3735252-A2 HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF Avidity Biosciences, Inc. (US) 2020-11-11 EP disclosed
EP-3720448-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY Avidity Biosciences, Inc. (US) 2020-10-14 EP disclosed
EP-3691657-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Avidity Biosciences, Inc. (US) 2020-08-12 EP disclosed
EP-3684376-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING Avidity Biosciences, Inc. (US) 2020-07-29 EP disclosed
WO-2020132584-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF AVIDITY BIOSCIENCES, INC. (US) 2020-06-25 WO disclosed
WO-2019136180-A2 HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF AVIDITY BIOSCIENCES LLC (US) 2019-07-11 WO disclosed
WO-2019113393-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY AVIDITY BIOSCIENCES LLC (US) 2019-06-13 WO disclosed
WO-2019071028-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES LLC (US) 2019-04-11 WO disclosed
WO-2019060775-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING AVIDITY BIOSCIENCES LLC (US) 2019-03-28 WO disclosed
EP-3436588-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Avidity Biosciences LLC (US) 2019-02-06 EP disclosed
WO-2017173408-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES LLC (US) 2017-10-05 WO disclosed
EP-2585113-A1 OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES DNA Therapeutics (FR) 2013-05-01 EP disclosed
WO-2012163814-A1 CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA INSTITUT CURIE (FR) 2012-12-06 WO disclosed
WO-2011161075-A1 OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES DNA THERAPEUTICS (FR) 2011-12-29 WO disclosed